Currently, there are 99.78M common shares owned by the public and among those 97.67M shares have been available to trade.
The company’s stock has a 5-day price change of -9.09% and 68.14% over the past three months. SLS shares are trading 65.22% year to date (YTD), with the 12-month market performance up to 82.69% higher. It has a 12-month low price of $0.77 and touched a high of $2.27 over the same period. SLS has an average intraday trading volume of 2.89 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.20%, 8.10%, and 43.60% respectively.
Institutional ownership of SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares accounts for 14.46% of the company’s 99.78M shares outstanding.
It has a market capitalization of $189.58M and a beta (3y monthly) value of 2.29. The earnings-per-share (ttm) stands at -$0.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.16% over the week and 8.76% over the month.
Earnings per share for the fiscal year are expected to increase by 36.67%, and -20.00% over the next financial year. EPS should shrink at an annualized rate of 33.56% over the next five years, compared to 45.94% over the past 5-year period.
Looking at the support for the SLS, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on July 21, 2021, with the firm’s price target at $18. H.C. Wainwright was of a view on April 02, 2018 that the stock is Buy, while Maxim Group gave the stock Buy rating on March 19, 2018, issuing a price target of $13.
